The aim of this work was to induce permanent tolerance toward self-antigens involved in autoimmune diseases, such as multiple sclerosis (MS). We hypothesized that the stable auto-antigen presentation by dendritic cells (DCs) would tolerize auto-reactive T cells and, therefore, prevent disease development in a mouse model of experimental autoimmune encephalomyelitis (EAE), which closely resembles MS. Specifically, our strategy included the ex vivo modification of hematopoietic stem cells (HSCs) with selfinactivating (SIN) lentivirus vectors that transcriptionally target the expression of myelin antigens to DCs. As SIN lentivirus vectors support the genomic integration of transgene sequences in HSC, the transduced and transplanted HSC may provide a constant supply of antigen expressing steady-state DCs. Here, we demonstrate that targeting myelin oligodendrocyte glycoprotein (MOG) expression to DCs indeed resulted in complete and stable protection from EAE. No histological signs of EAE, such as demyelination, axonal damage, or infiltration of leukocytes in brain, spinal cord and optical nerve, were observed in tolerized mice. Tolerance induction was concomitant with the efficient deletion of MOG-specific T cells and the generation of Foxp3 þ regulatory T cells and, most importantly, directed toward a specific self-antigen while T-cell reactivity to unrelated foreign antigens was fully preserved. 1 In fact, the major known genetic risk factors in MS reside in the major histocompatibility complex region, implicating major histocompatibility complex alleles and CD4 þ T cells in MS pathogenesis.
INTRODUCTION
Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are characterized by the activation and accumulation of antigen-presenting cells (APCs) and T cells within the central nervous system (CNS). Although the pathogenic mechanisms of MS remain unclear, several studies in animal models and patients indicate that auto-reactive T cells play a crucial role. 1 In fact, the major known genetic risk factors in MS reside in the major histocompatibility complex region, implicating major histocompatibility complex alleles and CD4 þ T cells in MS pathogenesis.
2 CD4 þ T cells reactive with several epitopes of myelin have indeed been identified, and it is possible that these T cells tend to be restricted by human leukocyte antigen alleles over-represented in MS patients. Some of the myelin proteins known to be recognized by self-reactive T cells include myelin basic protein, proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG). It is possible that differential human leukocyte antigen binding or lack of expression of certain myelin epitopes in the thymus results in poor negative selection of auto-reactive T cells, explaining the increase in the frequency of high-avidity T cells that recognize myelin epitopes in MS patients. 3 For example, MOG is known to trigger a demyelinating response in EAE, and has been reported to induce strong responses in MS patients. 4 However, investigation regarding lack of MOG expression in the thymus and consequent escape of MOG-specific T cells from negative selection has yielded contradictory results. 5, 6 A different myelin antigen, PLP, was also shown to be expressed at low levels in thymus of mice susceptible to EAE and, moreover, expression was largely restricted to the shorter splice variant, DM20. As PLP expression in the human thymus is also restricted to the DM20 isoform, lack of full-length PLP expression may be responsible for the escape of auto-reactive T cells and disease development. 7, 8 Although peripheral tolerance is expected to control self-reactive T cells evading central tolerance, an important feature of CNS immune privilege is that antigens expressed in CNS are sequestered and possibly not available for tolerance in the periphery. A clinical study demonstrated that a transient increase in myelin-reactive T cells coincided with higher disease activity, 9 thereby reinforcing the importance of auto-reactive T cells in MS. Therefore, therapies that aim at inducing antigen-specific tolerance are of great interest for the treatment of MS and other autoimmune diseases alike.
In an attempt to promote 're-education' of the immune system and prevent MS relapses, autologous hematopoietic stem cell (HSC) transplantation has been shown to be effective and beneficial in clinical trials of MS, 10 but disease relapse because of re-emergence of auto-reactive T cells suggests that treatment should consider the induction of permanent immune tolerance by immunotherapy. However, the major challenge for the widespread use of antigen-specific immunotherapy is to safely administer high doses of immunodominant and potentially pathogenic epitopes in a manner that induces T-cell tolerance rather than activation. 11 Therefore, the genetic manipulation of autologous HSC is a promising approach to treat autoimmune diseases such as MS. In this context, HSC transduction with viral vectors encoding self-antigens would lead to expression and presentation of the antigen and induction of antigen-specific tolerance.
Previous studies have shown that bone marrow (BM)-derived HSC (BM-HSC) transduced with gamma retrovirus vectors expressing MOG or PLP can protect mice from EAE. [12] [13] [14] However, these studies used ubiquitous promoters, which can mediate MOG expression in several types of hematopoietic cells. Moreover, standard and self-inactivating (SIN) gamma retrovirus vectors can cause insertional activation of oncogenes. 15 This risk may be reduced by directing transgene expression to a specific HSC descendant, such as dendritic cells (DCs), which have an important role in inducing and maintaining immunological tolerance and have a low propensity for proliferative disorders. Accordingly, Ko et al. 16 have used the CD11c promoter in the context of a SIN gamma retrovirus vector to direct MOG expression to DCs. While this strategy delayed disease onset, it did not prevent EAE development.
It was previously demonstrated that transduction of HSC with SIN lentivirus vectors expressing enhanced green fluorescent protein (EGFP) or ovalbumin (OVA) from the DC-specific transmembrane protein (DC-STAMP) promoter results in the transcriptional targeting of transgene expression to DCs and in antigen-specific tolerance induction. 17 In the present work, we successfully applied this approach to achieve DC-specific MOG expression, MOG-specific tolerance induction and prevention of EAE. The strategy presented here is particularly promising for clinical applications, because HSC isolated from the patient's BM are modified for permanent and continuous output of genetically modified tolerogenic 'steady-state' DCs. In addition, it is also an efficient tool for studying the immunoregulatory mechanisms that lead to tolerance establishment and maintenance.
RESULTS

SIN lentivirus vector mediates DC-specific antigen expression in vivo
To examine whether targeting the expression of a self-antigen to DCs can induce antigen-specific tolerance, we constructed a SIN lentivirus vector that expresses full-length murine MOG from the DC-specific STAMP promoter (DC-MOG; Figure 1a ). Control vectors expressing EGFP (DC-EGFP) or a membrane-targeted OVA (DC-OVA) from the DC-STAMP promoter have been described previously. 17 Vector-mediated MOG expression was demonstrated by immunofluorescence analysis of vector-transduced BMderived DCs (BM-DC) (data not shown). Furthermore, processing and presentation of MOG-derived peptides by DCs was functional as shown by T-cell proliferation assays using vector-transduced BM-DCs and CD4 þ T cells isolated from 2D2 mice, which are transgenic for a T-cell receptor (Va3.2 and Vb11 chains) that recognizes the MOG 35-55 peptide (Bettelli et al 18 ; Figure 1b ). The transcriptional specificity conferred by the DC-STAMP promoter was previously demonstrated 17 and confirmed here as follows: BM-HSCs from C57BL/6 Ly5.1 þ donor mice were transduced with DC-EGFP and then transplanted into lethally irradiated congenic Ly5.2 þ recipient mice. At 6 weeks after transplantation, we assessed EGFP expression in leukocytes isolated from spleens of chimeric mice. EGFP fluorescence was detected mainly in DC sub-populations, including CD8 þ DCs, CD11b þ DCs and plasmacytoid (p)DCs, and some monocytes, which are potential precursors of various DC sub-populations. Only a small percentage of B cells and CD4 þ and CD8 þ T cells were EGFP þ and the mean fluorescence intensities (MFI) of those cells were significantly lower than those of the DC subpopulations ( Figure 1c) .
As MOG-specific antibodies did not support detection of MOG by fluorescence-activated cell sorting (not shown), it was not possible to directly visualize DC-specific expression of MOG. Therefore, we constructed a SIN lentivirus vector that coexpressed MOG linked to EGFP via the 2A sequence of foot-andmouth disease virus (DC-EGFP/MOG, Figure 1a ). In chimeras generated by using this vector, the frequencies of EGFP þ cells and the MFI were smaller than in DC-EGFP chimeras (Figure 1d ), likely because of lower expression from the bi-cistronic transgene cassette. Nevertheless, the ratio of the numbers of EGFP þ cells and MFI between the different sub-populations of cells was comparable in DC-EGFP and DC-EGFP/MOG chimeras (compare Figures 1c and d) . Although in the DC-EGFP/MOG chimeras the percentage of EGFP þ pDCs was smaller than that of the monocytes, the MFI of the pDCs was significantly higher. Furthermore, functional MOG expression in the context of the DC-EGFP/MOG vector was confirmed in the experiment shown in Figure 6c (discussed below).
Transplantation of DC-MOG vector-transduced BM-HSC protects mice from EAE Next, we addressed if DC-targeted MOG expression can induce T-cell tolerance and protect mice from EAE. For this, lethally irradiated C57BL/6 mice were transplanted with DC-MOG or control vector (DC-OVA) transduced BM-HSC from congenic donors. After 8 weeks, EAE was induced by injection of 100 mg MOG peptide in complete Freund's adjuvant and pertussis toxin, and clinical signs of disease were assessed twice per day. We found that the control mice started to develop EAE at around day 10 after induction (mean onset day 10.5 ± 1.3), and that all animals reached clinical score 3 (at which point they were killed) within o1 week after disease onset (Figure 2a ). In contrast, none of the mice that received DC-MOG-transduced BM-HSC developed any neurological symptoms for at least 5 weeks after induction (clinical score 0, Figure 2a ). We observed similar results even when the animals were immunized 6 months after transplantation: animals remained protected from EAE ( Figure 2b ) and BM progenitors were able to give rise to MOG-expressing DCs, as determined by their capacity to induce the proliferation of MOG-specific CD4 þ T cells from 2D2 mice (Figure 2c ). We also investigated whether there were any subclinical signs of EAE in the protected mice. In accordance with the absence of clinical symptoms, histological analysis of the tolerized animals did not reveal any evidence of CNS pathology (Figures 3a and b) . By contrast, chimeras that received control vector-transduced BM-HSC (DC-OVA) showed extensive multifocal inflammatory infiltrates of mononuclear cells in optical nerve and spinal cord (Figures 3a and b ) and brain (data not shown). In addition, moderate-to-severe demyelination and axonal damage was observed in the affected tissues of DC-OVA but not of DC-MOG chimeras, as determined by staining of myelin and neurofilament, respectively ( Figure 3b ). As expected, the inflammatory process involved massive infiltration of macrophages and T cells in CNS tissues of diseased but not of protected mice (Figure 3b) . Accordingly, the frequency of CD4 þ T cells in the CNS of diseased animals was more than sevenfold higher than in protected mice (Figure 3c ). In the brain, mainly the meninges and the white matter were involved in the pathology, but rarely the gray matter (data not shown). In the spinal cord, the intensity of the demyelination and inflammatory process increased to the caudal parts (data not shown).
We analyzed cytokine production patterns from splenocytes of diseased and protected mice in response to in vitro re-stimulation with MOG peptide. As shown in Figure 4a , the concentration of Th2 cytokines (interleukin (IL)-4, IL-5 and IL-6) and inflammatory cytokines (IL-17, tumor necrosis factor-a, granulocyte-macrophage colony-stimulating factor and interferon (IFN)-g) was much higher in splenocytes of diseased DC-OVA control chimeras than in splenocytes of protected DC-MOG chimeras. A general impairment of cytokine production in the protected mice was ruled out, as splenocytes from diseased and protected mice produced comparable amounts of IFN-g on nonspecific stimulation with phorbol 12-myristate 13-acetate ( Figure 4a ). The concentration of Th2 and pro-inflammatory cytokines was also much higher in CNS homogenates of diseased mice compared with CNS homogenates from protected animals ( Figure 4b ). IL-10 was not detectable in CNS homogenates and, in splenocytes, IL-10 concentrations were not significantly different between DC-MOG and DC-OVA chimeras (data not shown).
To determine whether the tolerance induced was preserved also when the animals are challenged with an unrelated antigen, we immunized the chimeras simultaneously with both MOG and OVA peptide (100 mg each). As in the previous experiments in which EAE was induced through immunization with MOG peptide alone (Figure 2a ), control DC-OVA chimeras but not DC-MOG chimeras developed EAE on induction with MOG and OVA peptides ( Figure 5a ). Of note, we clearly demonstrate also that the tolerance induced was antigen-specific, because splenocytes from DC-MOG chimeras did not respond to re-stimulation with MOG peptide (Figure 5b ), yet produced IFN-g on re-stimulation with OVA peptide (Figure 5c ). Conversely, splenocytes from DC-OVA chimeras did not respond to stimulation with OVA peptide, but produced IFN-g when re-stimulated with MOG peptide (Figures 5b and c) . Taken together, these results indicate that MOG expression by DCs through transplantation of vectortransduced BM-HSC protects mice from EAE by inducing antigen-specific tolerance.
Transplantation of DC-MOG vector-transduced BM-HSC results in the depletion of MOG-specific T cells and induction of regulatory T cells (T reg )
We proceeded to investigate potential mechanisms of tolerance induction. To assess if MOG-specific T cells were deleted after encountering their cognate antigen, lethally irradiated C57BL/6 (Ly5.1) mice were transplanted with DC-MOG or DC-OVA vectortransduced BM-HSC isolated from 2D2 (Ly5.2) donors, and MOGspecific 2D2 T cells from the chimeras were quantified 6-8 weeks later. The results are shown in Figure 6 and can be summarized as follows: 2D2 T cells were largely depleted in chimeras that received DC-MOG vector-transduced BM-HSC, compared with animals that received control vector (DC-OVA)-transduced BM-HSC. In the DC-MOG-treated mice, only approximately 3% of the CD4 þ T cells in the spleen contained the Va3.2/Vb11 TCR, whereas approximately 61% of the CD4 þ T cells in the spleen of DC-OVA control vector-treated mice contained this MOG 35-55 -specific TCR (Figure 6a ). The total numbers of 2D2 T cells in spleen of DC-MOG-treated mice were also much lower than in DC-OVAtreated mice (Figure 6b ). The depletion of 2D2 T cells in DC-MOGtreated mice was less pronounced in thymus than in spleen but was nevertheless significant (Figures 6a and b) . The reduction of 2D2 T cells in thymus and spleen of DC-MOG chimeras was not due to a reduced chimerism, because 497% of thymocytes and 478% of splenocytes were of donor phenotype (as assessed by Ly5.2 expression; data not shown). The numbers of 2D2 T cells in spleens of DC-EGFP/MOG chimeras was also smaller than those of control DC-OVA chimeras (Figure 6c ), demonstrating that the former vector, which expresses MOG linked to EGFP via the 2A sequence and which was used to assess DC-specificity by fluorescence-activated cell sorting (Figures 1a and d) , can also induce the depletion of MOG-specific CD4 þ T cells. Analysis of the remaining 2D2 T cells of protected DC-MOG chimeras revealed an antigen-experienced phenotype, characterized by upregulation of CD25, CD44 and CD69, and slight downregulation of CD62L (Figure 7a ). More than 30% of these remaining 2D2 T cells in DC-MOG chimeras were CTLA-4 and Foxp3-positive, whereas o1% of the 2D2 T cells isolated from DC-OVA-treated mice showed this T reg phenotype (Figure 7b) . Also, the total numbers of 2D2 T reg cells were higher in spleen and thymus of DC-MOG chimeras than in spleen and thymus of control chimeras, respectively (Figure 7c ). The increased numbers of 2D2 T reg cells in the thymus of DC-MOG compared with DC-OVA chimeras suggests that natural T reg cells have been generated. Importantly, T reg cells from DC-MOG chimeras mediated a dosedependent suppression of 2D2 effector T-cell proliferation in presence of MOG 35-55 peptide-loaded DCs isolated from untreated C57BL/6 mice; the same numbers of T reg cells from DC-OVA chimeras did not have such an inhibitory effect (Figures  7d and e) . Taken together, these results indicate that constitutive DC-specific MOG expression mediated through lentiviral transduction simultaneously supports deletion of MOG-specific T cells and generation of MOG-specific T reg cells.
DISCUSSION
The current immunomodulators and immunosuppressants used for the management of MS have proven helpful, however, they have limited efficacy and often adverse side effects that include general immunosuppression. Therefore, it is important to design novel forms of therapy which abrogate harmful immune responses directed toward self-antigens while simultaneously conserving the ability of the immune system to combat pathogens and cancer. As anti-myelin T-cell reactivity is well documented in MS, antigen-specific therapy may be an effective treatment. In this regard, HSC transplantation coupled with gene therapy has emerged as a potential tool to treat autoimmune disorders by constitutively restoring immune system homeostasis. 19 In this work, we have transduced BM-HSC with a SINlentivirial vector that expresses MOG under transcriptional control of the DC-STAMP promoter. The capacity of this promoter to support transgene expression specifically in DCs has been demonstrated in a previous study, 17 and it was confirmed here (Figures 1c and d) . By targeting MOG expression to DCs, we achieved complete protection of mice from EAE development following immunization with MOG peptide and adjuvant (Figures  2a and b) . Although ubiquitous expression of myelin antigens regulated by retroviral promoters was previously shown to induce tolerance and EAE resistance, 12-14 the present work is the first to our knowledge, to (i) employ a lentivirus vector for tolerance induction in EAE/MS, (ii) render complete, long-term protection from EAE induction through transcriptionally targeting the expression of MOG to DCs, (iii) demonstrate the generation of myelin-specific functional T reg cells and (iv) demonstrate that EAE tolerance was induced toward a specific self-antigen while T-cell reactivity to unrelated foreign antigens was fully preserved. Recently, Ko et al. 16 used a similar approach to target MOG expression to DCs, using a gamma retrovirus vector expressing MOG from the CD11c promoter, but these investigators observed only a delay in EAE development. The inability to completely abrogate EAE in that work may have been due to low level antigen expression in DCs, which could be a result of lower transcriptional activity driven by the CD11c promoter compared with the DC-STAMP promoter used in our work; additionally, lentivirus vectors can more efficiently transduce quiescent cells, 20 such as HSC. Lentiviral vectors have the additional advantage that they are less prone to silencing effects than standard retrovirus vectors. 21 Indeed, we found that 6 months after reconstitution of the immune system with DC-MOG vector-transduced HSC, mice were still protected from EAE, and BM-DCs were still expressing/ presenting MOG to T cells (Figures 2b and c) . Because approximately 4% of B and T cells express the transgene, albeit at very low levels (Figure 1c) , it is possible that these cells Figure 3 . CNS histology of protected and diseased animals. BM-HSC from 5-fluorouracil-treated C57BL/6 donor mice were transduced with DC-MOG or DC-OVA and injected into lethally irradiated congenic recipient mice. After 8 weeks, mice were immunized with MOG peptide in complete Freund's adjuvant (CFA) (day 0) þ pertussis toxin (PTX) (days 0 and 2), and were monitored for neurological signs of EAE. The organs were isolated from DC-OVA chimeras when they reached score 3 and from DC-MOG chimeras after all control mice (DC-OVA) reached score 3. participate in the process of tolerance induction. T cells do not express major histocompatibility complex-II and therefore cannot present antigen and tolerize CD4 þ T cells directly, but they could serve as antigen source for APCs. In addition, other APCs could also acquire the antigen expressed by DCs in vivo. Despite the low amount of transgene expression in non-DCs, and despite the possible participation of non-DCs in tolerance induction, placing a DC-specific promoter in the lentivirus vector backbone minimizes the risk of uncontrolled cell proliferation because of integration of the virus near to proto-oncogenes because DCs have a small propensity for proliferative disorders.
We also showed that immunization of MOG-tolerized mice with an unrelated non-self-antigen (OVA) did not terminate the previously induced tolerance toward MOG (Figure 5a ), indicating that tolerance induction was antigen specific (Figures 5b and c) . This is an important finding because it demonstrates that although MOG-expressing DCs derived from lentivirus vectortransduced HSC are capable of priming T cells against foreign antigens in an inflammatory context (OVA in presence of potent adjuvants), such DCs did not reverse the tolerance phenotype among MOG-tolerized T cells. Furthermore, in contrast with splenocytes from diseased control mice, splenocytes isolated from DC-MOG mice produced no/low levels of Th1, Th2 or Th17 cytokines when re-stimulated in vitro with MOG peptide, and no significant difference was found between the experimental and control groups when the cells were stimulated with phorbol 12-myristate 13-acetate (Figure 4a ). Although tolerized animals had lower frequencies of MOG-specific T cells, these results suggest they were less responsive to MOG than the T cells of diseased control mice; furthermore they were not intrinsically impaired, as T-cell function toward MOG-unrelated stimulation was still intact.
In the experiments in which 2D2 mice were used as BM donors, we detected much lower numbers of MOG-specific CD4 þ T cells in the periphery and in the thymus of DC-MOG chimeras than of DC-OVA chimeras (Figures 6a and b) . This observation indicates that both peripheral and central deletional tolerance mechanisms were induced by transcriptionally targeting MOG expression to DCs, although it is unclear whether MOG antigen is presented directly or indirectly by DCs or other APCs. Interestingly, the vast majority of the MOG-specific CD4 þ T cells appeared to be deleted in the DC-MOG chimeras and 430% of the remaining cells had a T reg phenotype. We have not yet addressed whether only natural T reg cells were generated or also inducible T reg cells. The observed generation of T reg cells in the present work contrasts with a previous study in which a retroviral vector that expressed MOG from a ubiquitous promoter was used to transduce HSC. In that study, deletional tolerance of MOG-specific T cells was observed, but not the generation of CD4 þ Foxp3 þ T reg cells. 12 In a different report, DC targeting with MOG was achieved using an antibody that binds to DEC-205, an endocytic receptor expressed by the CD8 þ DC sub-population. Although this approach rendered MOGspecific unresponsiveness and prevention of EAE, it did not lead to T-cell deletion or generation of T reg cells. 22 Although we did not directly show the requirement of T reg cells for protection from EAE in our study, we demonstrate that T reg cells from DC-MOG chimeras had the capacity to suppress the proliferation of 2D2 effector T cells when co-cultured with MOG 35-55 peptide-loaded DCs (Figure 7e) . A combination of deletional tolerance and generation of T reg cells may be desirable for the therapeutic induction of tolerance in an autoimmune disease setting.
Several studies suggest that in addition to CD4 þ T cells, CD8 þ T cells play an important role in the pathogenesis of MS. CD8 þ T cells are found in larger numbers than CD4 þ T cells in MS lesions, and these CD8 þ T cells exhibit more clonal expansion than CD4 þ T cells. 23 Therefore, tolerance mechanisms that restrain activity of both populations of myelin-specific T cells are needed. In this study, we did not address MOG-specific CD8 þ T-cell tolerance induction, but we can speculate that this occurs, because in a recent report in which OVA was transcriptionally targeted to DCs with the DC-STAMP promoter, robust tolerance was observed in both CD4 þ and CD8 þ T-cell compartments. 17 As we transcriptionally targeted full-length MOG expression to DCs, we can expect that MOG antigens being presented in the major histocompatibility complex-I context would also lead to CD8 þ T-cell tolerance.
In conclusion, our results show that complete and long-lasting protection from an autoimmune disease can be achieved by combining SIN lentiviral vector-mediated transduction of HSC together with transcriptionally targeting self-antigen expression to DCs. This approach recruited two mechanisms of tolerance: generation of antigen-specific T reg cells and deletion of MOGspecific T cells. The roles that each of these mechanisms have in providing protection from EAE still need to be assessed. Most importantly, T-cell tolerance was induced toward a specific antigen, whereas preserving full T-cell reactivity to unrelated foreign antigens. Therefore, this is a promising strategy not only for the treatment of MS, but also for other autoimmune diseases in which the self-antigen involved is known. respectively. The BglII-AfeI fragment containing the 2A sequence and the AfeI-EcoRI fragment containing the tfr-ova sequence were ligated together between the BglII and EcoRI sites of pEGFP-C1 (Clontech, St. Germain, Switzerland). From the resulting plasmid, the AgeI-EcoRI fragment, containing the EGFP-2A-tfr-ova sequence was cloned between the AgeI and EcoRI sites of the lentivirus vector plasmid FUG4. 17 The resulting plasmid was designated FUG60 and encodes the EGFP-2A-tfr-ova sequence from the DC-STAMP promoter. Finally, DC-EGFP/MOG was constructed by replacing the AfeI-EcoRI fragment containing the tfr-ova sequence in FUG60 with an AfeI-EcoRI fragment obtained by PCR amplification with primers 39 (see above) and 65 (5 0 -GAAAAGCGCTATGG CCTGTTTGTGGAGCTT-3 0 ) using pFLC1 (ImaGenes GmbH) as template. SIN lentivirus vector stocks were prepared and titrated essentially as described previously. 17 BM chimeras BM cells of at least 6 weeks old female C57BL/6 or 2D2 mice were harvested 4 days after intravenous injection of 5-fluorouracil (150 mg kg À 1 body weight; Sigma-Aldrich, Buchs, Switzerland). The cells were pre-stimulated for 2 days in serum-free HSC expansion medium (Stemline, Sigma-Aldrich) supplemented with penicillin-streptomycin (Life Technologies, Invitrogen, Paisley, UK) and a growth factor mixture containing human IL-6 (25 ng ml ) and murine stem cell factor (50 ng ml À 1 ). Recombinant growth factors were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Cells were transduced by spin infection (300 Â g; 2h; 321C) with cell-free stocks of SIN lentivirus vector (multiplicity of infection ¼ 30) in the presence of protamine sulfate (4 mg ml 
MATERIALS AND METHODS
CNS histopathology
Brain and optical nerve were fixed in 4% formaldehyde and embedded in paraffin. Spinal cord was left in the vertebrae and, after fixation, decalcified for 2 weeks with 25% EDTA before paraffin embedding. For histochemical and immunohistochemical staining, 3 mm thick slides were deparaffinated with xylol and alcohol and either stained with hematoxylin and eosin or processed as follows: For assessing demyelination, the slides were incubated in luxol fast blue (MBS, Dr Bender and Dr Hobein, Zurich, Switzerland) and counterstained with crysol violet (Fluka AG, Buchs, Switzerland). For immunohistochemical staining, the slides were stained with the following antibodies: rat anti-mouse anti-Mac3 (macrophages; 1:10; BD Pharmingen, Hamburg, Germany), mouse anti-SMI 32 (neurofilament; 1:400; Abcam, Cambridge, UK), or rabbit anti-mouse CD3 (T-cells; 1:100; Ventana Medical Systems, Inc., Tucson, AZ, USA).
BM-DC and in vitro T-cell proliferation assay BM cells were extracted from femur and tibia and cultured in six-well plates at 37 1C in RPMI 1640 medium (Invitrogen, Basel, Switzerland) supplemented with 10% fetal bovine serum (BioConcept, Allschwil, Switzerland), 1% penicillin-streptomycin (Life Technologies), 0.1 mM Hepes (Invitrogen) and DC differentiation factor granulocyte-macrophage colonystimulating factor (40 ng ml À 1 ; Miltenyi Biotec). At day 6, 5 Â 10 4 DCs were pre-incubated for 2 h at 37 1C with MOG 35-55 peptide (2 mg ml À 1 ) and then co-cultured in a total volume of 100 ml in a 96-well plate (Becton Dickinson, Le Pont De Claix, France) with 5 Â 10 4 2D2 T cells which have previously been labeled with 2.5 mM of carboxyfluorescein succinimidyl ester. The proliferation of 2D2 T cells was analyzed by flow cytometry 4 days later.
Cytokine analysis
Cytokines were measured in the spleen by in vitro splenocyte stimulation. For this, splenocytes were cultured in six-well plates (1 Â 10 7 cells per well) in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (BioConcept), 1% penicillin-streptomycin (Life Technologies), 0.1 mM Hepes (Invitrogen), 2 mM L-glutamine (Invitrogen) and 0.01 mM non-essential amino acids (Invitrogen). Splenocytes were þ CD25 þ T reg cells was measured at two different T reg cell/2D2 effector T-cell ratios (Treg/Teff ) by carboxyfluorescein succinimidyl esterdilution of proliferated 2D2 T cells. Plots represent individual animals from three independent experiments. *P ¼ 0.0244; **P ¼ 0.0061; ***P ¼ 0.0005; ****Po0.0001.
